

- Tsurumoto T, Tsuji Y, Sonemoto E, Shimasaki N, Koyanagi S, Sasaki H, Ieiri I, Higuchi S, Kawakami A, Ueki Y, Eguchi K. Methotrexate chronotherapy is effective against rheumatoid arthritis. *Chronobiol Int.* 2011;28(267-274)
- 5) Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the registry of Japanese rheumatoid arthritis patients for longterm safety. *J Rheumatol.* 2011;38(1258-1264)
- 6) Origuchi T, Iwamoto N, Kawashiri SY, Fujikawa K, Aramaki T, Tamai M, Arima K, Nakamura H, Yamasaki S, Ida H, Kawakami A, Ueki Y, Matsuoka N, Nakashima M, Mizokami A, Kawabe Y, Mine M, Fukuda T, Eguchi K. Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor. *Mod Rheumatol.* 2011; 21(244-250)
- 7) Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Satoh K, Tamai M, Nakamura H, Okada A, Koga T, Yamasaki S, Ida H, Origuchi T, Eguchi K. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis. *Rheumatology (Oxford).* 2011;50(962-965)
- 8) Hida A, Akahoshi M, Takagi Y, Imaizumi M, Sera N, Soda M, Maeda R, Nakashima E, Ida H, Kawakami A, Nakamura T, Eguchi K. Lipid infiltration in the parotid glands: a clinical manifestation of metabolic syndrome. *Exp Clin Endocrinol Diabetes.* 2012; 120(110-115)
- 9) Ichinose K, Origuchi T, Kawashiri SY, Iwamoto N, Fujikawa K, Aramaki T, Kamachi M, Arima K, Tamai M, Nakamura H, Ida H, Kawakami A, Eguchi K. Long-term follow-up of adalimumab monotherapy for rheumatoid arthritis in Japanese patients: a report of six cases. *Rheumatol Int.* 2012;32(483-487)
- 10) Kawashiri SY, Kawakami A, Okada A, Koga T, Tamai M, Yamasaki S, Nakamura H, Origuchi T, Ida H, Eguchi K. CD4+CD25highCD127low/- Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis. *J Rheumatol.* 2011;38(2517-2521)
- 11) Kita J, Tamai M, Arima K, Nakashima Y, Suzuki T, Kawashiri SY, Iwamoto N, Okada A, Koga T, Yamasaki S, Nakamura H, Origuchi T, Ida H, Aoyagi K, Uetani M, Eguchi K, Kawakami A. Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration. *Mod Rheumatol.* 2011 Sep 30. [Epub ahead of print]
- 12) Kita J, Tamai M, Arima K, Nakashima Y, Suzuki T, Kawashiri SY, Okada A, Koga T, Yamasaki S, Nakamura H, Origuchi T,

- Aramaki T, Nakashima M, Fujikawa K, Tsukada T, Ida H, Aoyagi K, Uetani M, Eguchi K, Kawakami A. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors. *Mod Rheumatol*. 2011 Sep 6. [Epub ahead of print]
- 13) Tamai M, Kawakami A, Uetani M, Fukushima A, Arima K, Fujikawa K, Iwamoto N, Aramaki T, Kamachi M, Nakamura H, Ida H, Origuchi T, Aoyagi K, Eguchi K. Magnetic resonance imaging (MRI) detection of synovitis and bone lesions of the wrists and finger joints in early-stage rheumatoid arthritis: comparison of the accuracy of plain MRI-based findings and gadolinium-diethylenetriamine pentaacetic acid-enhanced MRI-based findings. *Mod Rheumatol*. 2011 Dec 28. [Epub ahead of print]
- 14) Iwamoto N, Kawakami A, Tamai M, Arima K, Nakamura H, Kawashiri SY, Kita J, Okada A, Koga T, Kamachi M, Yamasaki S, Ichinose K, Ida H, Origuchi T, Uetani M, Eguchi K. Magnetic resonance imaging of wrist and finger joints distinguishes secondary Sjögren's syndrome with rheumatoid arthritis from primary Sjögren's syndrome with articular manifestations. *Clin Exp Rheumatol*. 2011; 29(1062-1063)
- 15) 井田弘明, 吉浦孝一郎, 金澤伸雄: 特集Ⅱ 自己炎症症候群 中條-西村症候群の臨床と病態. *炎症と免疫* 2011;19(153-157)
- 16) 井田弘明: 自己炎症症候群の遺伝子異常. *内科* 2011;107(645-652)
- 17) 井田弘明: 医学用語解説 プロテアソーム. *炎症と免疫* 2011; 19(297-299)
- 18) 井田弘明: 自己炎症症候群と自然免疫. *リウマチ科* 2011;46(149-154)
- 19) 金澤伸雄, 有馬和彦, 井田弘明, 吉浦孝一郎, 古川福実: 中條-西村症候群. *日本臨床免疫学会誌* 2011;34(388-400)

2. 学会発表

国内学会

第 55 回日本リウマチ学会総会・学術集会
2011.7.17-7.20 神戸市

シンポジウム 井田弘明 成人の自己炎症性疾患の炎症病態

野中文陽, 江口勝美, 右田清志, 井田弘明, 川上純: MEFV R202Q 変異を認めた IMAM (inflammatory Myopathy with Abundant Macrophages) の 1 例

吉田つかさ, 本多靖洋, 海江田信二郎, 丸岡浩誌, 福田孝昭, 井田弘明: SLE に合併した蛋白漏出胃腸症の一例

荒牧俊幸, 中島宗敏, 古賀智裕, 川尻真也, 山崎聡士, 中村英樹, 本多靖洋, 井田弘明, 折口智樹, 福田孝昭, 江口勝美, 川上純: タクロリムスのループス腎炎に対する有用性の検討 一前向き試験一

藤秀人, 井田弘明, 曾根本恵美, 佐々木均, 植木幸孝, 江口勝美: 関節リウマチ治療におけるメトトレキサートの時間薬物療法

上田尚靖, 塚本浩, 石ヶ坪良明, 楠原浩一, 武井修治, 蓑田清次, 鷲尾昌一, 井田弘明, 高橋裕樹, 藤井隆夫, 田平知子, 大田俊一郎, 田中淳, 藤健太郎, 古川牧緒, 井上靖, 有信洋二郎, 新納宏昭, 赤司浩一, 堀内孝彦: TNF 受容体関連周期性症候群 (TRAPS) の全国実態調査

金澤伸雄, 古川福実, 井田弘明: 中條-西村症候群: 新規幼児例の報告と類似疾患の外国報告例との比較

有馬和彦, 井田弘明, 折口智樹, 金澤伸雄, 江口勝美: 全身性炎症を呈する遺伝性プロテアソーム機能不全症の発見

田尻守弘, 井田弘明, 海江田信二郎, 本多靖洋, 福田孝昭: 膠原病関連間質性肺炎と特発性間質性肺炎との差異; 気管支肺胞洗浄分析から

第 41 回九州・沖縄支部学術集会 (九州リウマチ学会) 2011.3.19-20 宮崎市

本多靖洋, 勝目茉紗子, 井田弘明, 海江田信二郎, 吉田つかさ, 矢野真弓, 竹尾正影, 松岡昌信, 日高由紀子, 弓削健太郎, 福田孝昭: 猛暑の真夏に発症したリベドを伴う有通性皮膚潰瘍

本多靖洋, 海江田信二郎, 井田弘明, 矢野真弓, 竹尾正影, 松岡昌信, 日高由紀子, 福田孝昭, 弓削健太郎 児希望関節リウマチ患者へエタネルセプトの継続投与を行い、妊娠・出産・授乳した 3 症例

第 32 回日本炎症・再生医学会
2011.06.02-03 京都市

井田弘明, 有馬和彦, 金澤伸雄, 江口勝美: プロテアソーム機能不全症 (中條-西村症候群) の病態解析

金澤伸雄, 井田弘明: 中條-西村症候群 (家族性日本熱) と脂肪萎縮を伴う自己炎症疾患

国際学会

10th World Congress on Inflammation

2011.06.25-29 Paris

Ida H, Arima K, Kinoshita A, Mishima H, Kanazawa N, Furukawa F, Murata S, Yoshiura K-I, Eguchi K A novel mutation of proteasome subunit causes decrease of proteasome activity in Nakajo-Nishimura syndrome (familial Japanese fever)

Kanazawa N, Kunimoto K, Mikita N, Furukawa F, Yoshiura K-I, Ida H Nakajo-Nishimura syndrome (familial Japanese fever) and related auto-inflammatory disorders accompanied with lipodystrophy

Annual European Congress of Rheumatology (EULAR 2011) 2011.5.25-28 London

Arima K, Kanazawa N, Mishima H, Kinoshita A, Ida H, Yoshiura K, Eguchi K Decrease of proteasome activity is associated with a novel mutation of the proteasome catalytic subunit in an autoinflammatory disorder, Nakajo-Nishimura syndrome.

75th annual meeting of the American College of Rheumatology (ACR 2011) 2011.11.5-9 Chicago

Ida H, Arima K, Kanazawa N, Yoshiura KI Proteasome disability syndrome: an analysis of the pathogenesis of a new autoinflammatory syndrome, Nakajo-Nishimura syndrome

H. 知的財産権の出願・登録状況
(予定を含む)

1. 特許取得

「自己炎症疾患又は自己免疫疾患関連遺伝子及びその利用」発明者（長崎大学：吉浦孝一郎、久留米大学：井田弘明、和歌山県立医科大学：金澤伸雄） 出願番号：特願2011-177269

IV. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

(竹内 勤)

[雑 誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tanaka Y, Yamanaka H, Saito K, Iwata S, Miyagawa I, Seto Y, Momohara S, Nagasawa H, Kameda H, Kaneko Y, Izumi K, Amano K, <u>Takeuchi T</u>	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept.	Mod Rheumatology		in press	
Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, <u>Takeuchi T</u> , Takei S, Tanaka Y, Ito K, Yamanaka H	Concise report: Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.	Ann Rheum Dis	70	2148-2151	2011
Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, <u>Takeuchi T</u> , Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with Rheumatoid Arthritis.	Mod Rheum	21	343-351	2011
<u>Takeuchi T</u> , Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, Kubo S, Shidara K, Kimura N, Nagasawa H, Kameda H, Amano K, Yamanaka H	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: Retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).	Mod Rheumatology	Online 6, Sep		2011
Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, <u>Takeuchi T</u>	Continuation of Methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with Rheumatoid Arthritis: 52-Week results from the JESMR Study.	J Rheum	38	1585-1592	2011
Kaneko Y, Kuwana M, Kameda H, <u>Takeuchi T</u>	Sensitivity and Specificity of 2010 Rheumatoid Arthritis Classification Criteria	Rheumatology	50	1268-74	2011

Komano Y, Tanaka M, Nanki T, Kameda H, Atsumi T, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, <u>Takeuchi T</u> , Miyasana N, Harigai M, et al.	Incidence and risk factors for serious infection in rheumatoid arthritis patients treated with tumor necrosis factor (TNF) inhibitors: a report from the registry of Japanese Rheumatoid Arthritis Patients for Long-Term Safety.	J Rheum	38	1258-64	2011
Suzuki K, Setoyama Y, Yoshimoto K, Tsuzaka K, Abe T, <u>Takeuchi T</u>	Decreased mRNA expression of two Foxp3 isoforms in peripheral blood mononuclear cells from patients with rheumatoid arthritis and systemic lupus erythematosus.	Int J Immunopathol and Pharmacology	24	7-14	2011
Hashimoto J, Garnero P, van der Heijde, Miyasaka N, Yamamoto K, Kawai S, <u>Takeuchi T</u> , Yoshikawa H, Nishimoto N	Humanized anti-interleukin 6 receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study.	Modern Rheum	21	10-15	2011
<u>Takeuchi T</u> , Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Satoh E, Saitao K, Kaneko Y, Fukuyo S, Kurasawa T, Hanami K, Kameda H, Yamanaka H	Clinical, radiographic, and functional effectiveness of tocilizumab for rheumatoid arthritis patients - REACTION-52 weeks study.	Rheumatology	On line July 13		2011
Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, Da Silva JP, de Wit M, Dougados M, Durez P, Emery P, Fonseca JE, Gibfsky A, Gomez-Reino J, Graninger W, Hamuryudan V, Jannaut Peya MJ, Kalden J, Kvien TK, Laurindo I, Martin-Mola E, Montecucco C, Moreno PS, Pavelka K, Poor G, Cardiel MH, Stanislawski-Biernat E, <u>Takeuchi T</u> , van der Heijde D, the Treat to Target Taskforce	Treating Rheumatoid Arthritis to Target: multinational recommendatio assessment questionnaire.	Ann Rheum Dis	On line July 29		2011

Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, <u>Takeuchi T</u>	Efficacy of tocilizumab for rheumatoid arthritis patients in daily practice in Japan –message from REACTION study.	Modern Rheum	21	122-33	2011
Okuyama A, Nagasawa H, Suzuki K, Kameda H, Kondo H, Amano K, <u>Takeuchi T</u>	Fc gamma receptor IIIb polymorphism and usage of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.	Ann Rheum Dis	70	299-304	2011
<u>Takeuchi T</u> , Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T	Baseline tumor necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.	Ann Rheum Dis	70	1208-15	2011

(小池 隆夫)

[雑 誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Koike T	The new era of autoimmune disease research	Arthritis Research & Therapy	13	113	2011
Kato M, Atsumi T, Kurita T, Odani T, Fujieda Y, Otomo K, Horita T, Yasuda S, Koike T	Hapatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: Risk analysis in hepatitis B surface antigen-negative cases.	J Rheumatol	38(10)	2209-14	2011
Fukae J, Isobe M, Kitano A, Henmi M, Sakamoto F, Narita A, Ito T, Mitsuzaki A, Shimizu M, Tanimura K, Matsuhashi M, Kamishima T, Atsumi T, Koike T.	Radiographic prognosis of finger joint damage predicted by early alteration in synovial vascularity predicts radiographic prognosis of finger joint damage in patients with rheumatoid arthritis: Potential utility of power doppler sonography in clinical practice.	Arthritis Care Res	63(9)	1247-53	2011
Koike T	IFN γ independent suppression of Th-17 differentiation by T-bet expression in autoimmune arthritis mice	Arthritis Rheum	13(1)	40-1	2012

(山本 一彦)

[雑 誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Okada Y, Shimane K, Kochi Y, Tahira T, Suzuki A, Higasa K, Takahashi A, Horita T, Atsumi T, Ishii T, Okamoto A, Fujio K, Hirakata M, Amano H, Kondo Y, Ito S, Takada K, Mimori A, Saito K, Kamachi M, Kawaguchi Y, Ikari K, Mohammed O W, Matsuda K, Terao C, Ohmura K, Myouzen K, Hosono N, Tsunoda T, Nishimoto N, Mimori T, Matsuda F, Tanaka Y, Sumida T, Yamanaka H, Takasaki Y, Koike T, Horiuchi T, Hayashi K, Kubo M, Kamatani N, Yamada R, Nakamura Y, <u>Yamamoto K</u>	A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupuseyrthematosus in Japanese.	PLoS Genet		in press	
Kochi Y, Thabet MM, Suzuki A, Okada Y, Daha NA, Toes REM, Huizinga TWJ, Myouzen K, Kubo M, Yamada R, Nakamura Y, <u>Yamamoto K</u>	PADI4 polymorphism predisposes male smokers to rheumatoid arthritis.	Ann Rheum Dis	70	515-5	2011

(山中 寿)

[雑 誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Yamanaka H</u> , Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, <u>Takeuchi T</u>	Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).	Mod Rheumatol	21(2)	122-33	2011
Tanaka Y, Suzuki M, Nakamura H, Toyozumi S, Zwillich SH; <u>Tofacitinib Study Investigators</u>	Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.	Arthritis Care Res (Hoboken)	63(8)	1150-8	2011
Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, <u>Takeuchi T</u> , Tanaka Y, <u>Yamanaka H</u> , Fujii K, Yoshinaga T, Freundlich B, Suzukawa M	Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study.	Rheumatol Int		in press	
Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, <u>Takeuchi T</u> , Tanaka Y, <u>Yamanaka H</u> , Fujii K, Yoshinaga T, Freundlich B, Suzukawa M	Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis.	Rheumatol Int		in press	
Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, <u>Takeuchi T</u> , Tanaka Y, <u>Yamanaka H</u> , Fujii K, Yoshinaga T, Freundlich B, Suzukawa M	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis.	Mod Rheumatol	21(4)	343-51	2011
<u>Takeuchi T</u> , Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Sato E, Saito K, Kaneko Y, Fukuyo S, Kurasawa T, Hanami K, Kameda H, <u>Yamanaka H</u>	Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients – REACTION 52-week study.	Rheumatology (Oxford)	50(10)	1908-15	2011

Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, <u>Takeuchi T</u> , <u>Yamanaka H</u> , Tanaka Y	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.	Mod Rheumatol	in press		
Tanaka Y, <u>Yamanaka H</u> , Saito K, Iwata S, Miyagawa I, Seto Y, Momohara S, Nagasawa H, Kameda H, Kaneko Y, Izumi K, Amano K, <u>Takeuchi T</u>	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept.	Mod Rheumatol	in press		
Tanaka Y, Harigai M, <u>Takeuchi T</u> , <u>Yamanaka H</u> , Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Oba T, Yoshinari T, Baker D; the GO-FORTH Study Group	Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study.	Ann Rheum Dis	in press		
Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, <u>Takeuchi T</u> , Takei S, Tanaka Y, Ito K, <u>Yamanaka H</u>	Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.	Ann Rheum Dis	70(12)	2148-51	2011

(田中 良哉)

[雑誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tanaka Y, Maeshima Y, Yamaoaka K	In vitro and in vivo analysis of a Jak inhibitor in rheumatoid arthritis.	Ann Rheum Dis	in press		
Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, et al.	Clinical, radiographic, and functional effectiveness of tocilizumab for rheumatoid arthritis patients – REACTION 52 – week study – .	Rheumatology	in press		
Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Tanaka Y, Ito K, et al.	Postmarketing Surveillance of Tocilizumab for Rheumatoid Arthritis in Japan – Interim Analysis of 3,881 Patients.	Ann Rheum Dis	in press		

Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al.	Golimumab, a human anti-TNF- α monoclonal antibody, injected subcutaneously every 4 weeks in Japanese patients with active rheumatoid arthritis in combination with methotrexate: results of the Phase 2/3, multicenter, randomized, double-blind, placebo-controlled GO-FORTH study through 24 weeks.	Ann Rheum Dis	in press		
Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, Tanaka Y, Bingham III CO, et al.	Efficacy and safety of ocrelizumab in patients with active rheumatoid arthritis with an inadequate response to at least one TNF inhibitor: results from the phase III SCRIPT trial.	Arthritis Rheum	in press		
Harigai M, Tanaka Y, Maisawa S; on behalf of the JA21963 study group.	Safety and efficacy of various dosages of ocrelizumab in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate therapy: a placebo-controlled, double-blind, parallel-group study.	J Rheumatol	in press		
Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Tanaka Y, et al.	A JAK inhibitor tofacitinib regulates synovitis through inhibition of IFN- γ and IL-17 production by human CD4 ⁺ T cells.	Arthritis Rheum	in press		
Oshita K, Yamaoka K, Udagawa N, Fukuyo S, Sonomoto K, Tanaka Y	Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production.	Arthritis Rheum	63	1658-1667	2011
Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Tanaka Y	Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naïve T-cells and a D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model.	J Immunol	186	3745-3752	2011
Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Tanaka Y, et al.	Continuation of Methotrexate (MTX) Resulted in Better Clinical and Radiographic Outcomes than Its Discontinuation upon Commencing Etanercept in Patients with Rheumatoid Arthritis: 52-Week Results from the JESMR Study.	J Rheumatol	38	1585-1592	2011
Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Tanaka Y	Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.	J Rheumatol	38	633-641	2011

Komano Y, Tanaka M, Nanki T, Tanaka Y, Miyasaka N, Harigai M, et al.	Incidence and risk factors for serious infection in rheumatoid arthritis patients treated with tumor necrosis factor (TNF) inhibitors; a report from the registry of Japanese Rheumatoid Arthritis Patients for Long-Term Safety (REAL).	J Rheumatol	38	1258-1264	2011
Tanaka Y, Suzuki M, Nakamura H, Toyozumi S, Twillich S	Phase 2 study of tofacitinib (CP-690, 550) combined with methotrexate in patients with rheumatoid arthritis and inadequate response to methotrexate.	Arthritis Care Res	63	1150-1158	2011

(西本 憲弘)

[雑誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Yoshikawa H, <u>Nishimoto N</u>	Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study.	Mod Rheumatol	21	10-15	2011
Lee HM, Sugino H, Aoki C, <u>Nishimoto N</u>	Underexpression of mitochondrial-DNA encoded ATP synthesis-related genes and DNA repair genes in systemic lupus erythematosus.	Arthritis Res Ther 15	13(2)	R63 [Epub ahead of print]	2011
Hirao M, Nampei A, Shi K, Yoshikawa H, <u>Nishimoto N</u> , Hashimoto J	Diagnostic features of mild cellulitis phlegmon in patients with rheumatoid arthritis treated with tocilizumab: a report of two cases.	Mod Rheumatol		[Epub ahead of print]	2011
Murakami M, <u>Nishimoto N</u>	The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.	Curr Opin Rheumatol	23(3)	273-7	2011
Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, Nerome Y, Iwata N, Murata T, Miyoshi M, <u>Nishimoto N</u> , Kishimoto T	Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis.	Mod Rheumatol		[Epub ahead of print]	2011

Lee HM, Sugino H, Aoki C, Shimaoka Y, Suzuki R, Ochi K, Ochi T, <u>Nishimoto N</u>	Abnormal networks of immune response-related molecules in bone marrow cells from patients with rheumatoid arthritis as revealed by DNA microarray analysis.	Arthritis Res Ther	13(3)	R89	2011
Hoshi D, Nakajima A, Inoue E, Shidara K, Sato E, Kitahama M, Seto Y, Tanaka E, Urano W, Ichikawa N, Koseki Y, Momohara S, Taniguchi A, <u>Nishimoto N</u> , Yamanaka H	Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab	Mod Rheumatol	[Epub ahead of print]		2011
Hirao M, Yamasaki N, Oze H, Ebina K, Nampei A, Kawato Y, Shi K, Yoshikawa H, <u>Nishimoto N</u> , Hashimoto J	Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab.	Rheumatol Int	[Epub ahead of print]		2011
Mori S, Tokuda H, Sakai F, Johkoh T, Mimori A, <u>Nishimoto N</u> , Tasaka S, Hatta K, Matsushima H, Kaise S, Kaneko A, Makino S, Minota S, Yamada T, Akagawa S, Kurashima A; and the NTM-BIORA (NTM infection in Biologic-treated RA patients) Study Investigators	Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan.	Mod Rheumatol	[Epub ahead of print]		2011

(石黒 直樹)

[雑誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, Takagi H, Yabe Y, Kato T, Ito T, Terabe K, Fukaya N, Kanayama Y, Shioura T, Funahashi K, Hayashi M, Kato D, Matsubara H, Fujibayashi T, Kojima M, Ishiguro N	Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) Study.	Mod Rheumatol			DOI: 10.1007/s10165-011-0518-4.
Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Takagi H, Yabe Y, Kato T, Terabe K, Fukaya N, Tsuchiya H, Shioura T, Funahashi K, Hayashi M, Kato D, Matsubara H, Ishiguro N	Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice.	Mod Rheumatol			DOI: 10.1007/s10165-011-0528-2
Hayashi M, Kojima T, Funahashi K, Kato D, Matsubara H, Shioura T, Kanayama Y, Hirano Y, Ishiguro N	Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.	Mod Rheumatol			DOI: 10.1007/s10165-011-0527-3
Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Tsuboi S, Ishiguro N	Anti-tumor necrosis factor therapy in rheumatoid arthritis patients with a history of deep prosthetic joint infection: a report of four cases.	Mod Rheumatol	21(5)	542-7	2011
Hayashi M, Kadomatsu K, Kojima T, Ishiguro N	Keratan sulfate and related murine glycosylation can suppress murine cartilage damage in vitro and in vivo.	Biochem Biophys Res Commun	409(4)	732-7	2011
Hiraiwa H, Sakai T, Mitsuyama H, Hamada T, Yamamoto R, Omachi T, Ohno Y, Nakashima M, Ishiguro N	Inflammatory effect of advanced glycation end products on human meniscal cells from osteoarthritic knees.	Inflamm Res	60(11)	1039-48	2011
Yoda M, Sakai T, Mitsuyama H, Hiraiwa H, Ishiguro N	Geranylgeranylacetone suppresses hydrogen peroxide-induced apoptosis of osteoarthritic chondrocytes.	J Orthop Sci	16(6)	791-8	2011

(針谷 正祥)

[書 籍]

発表者氏名	論文タイトル名	書籍全体の編集者名	出版社名	出版年
		書籍名	出版地	ページ
<u>針谷正祥</u>	生物学的製剤のリスクマネジメントとインフォームドコンセントとは?	宮坂信之編	医薬ジャーナル社	2011
		関節リウマチ (生物学的製剤の正しい使い方とは?)	日本	66-73

[雑 誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>針谷正祥</u>	日本の生物学的製剤使用ガイドライン (特集 世界のリウマチガイドラインをみわたす)	分子リウマチ治療	4(2)	27(77)-30(80)	2011
<u>針谷正祥</u>	日常臨床とファーマコビジランス (薬害監視) (特集 全身性疾患と腎障害)	総合臨床	60(6)	1451-1452	2011
<u>針谷正祥</u>	治療目標—目標達成に向けた治療 (Treat to Target) のエビデンスと実際	別冊・医学のあゆみ (関節リウマチ” 治癒をめざす” 最新治療コンセンサス)	別冊	14-19	2011
<u>針谷正祥</u> 、野々村美紀、酒井良子	REAL コホートにおける検証 (特集 2010 関節リウマチ新分類基準を検証する)	分子リウマチ治療	4(4)	15-18 (193-196)	2011
渡部香織、 <u>針谷正祥</u>	関節リウマチ患者が妊娠した場合に生物学的製剤は継続すべきか中止すべきか? (特集) 内科診療における論点	内科	107(6)	1411-1416	2011
萩山裕之、 <u>針谷正祥</u>	抗体療法の副作用対策	医学のあゆみ	238(6)	637-642	2011
長坂憲治、 <u>針谷正祥</u>	生物学的製剤の利点と欠点 (特集 ここまでわかった自己免疫疾患)	臨床検査 (増刊号)	55(11)	1349-1358	2011
山崎隼人、 <u>針谷正祥</u>	エタネルセプトは週 1 回投与が可能。(特集:生物学的製剤時代の関節リウマチ最新治療戦略)	Mebio (Graphic Medical Magazine)	29(1)	47-53	2012
<u>Harigai M</u> , Tanaka Y, Maisawa S	Safety and Efficiency of Various Dosages of Ocrelizumab in Japanese Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate Therapy: A Placebo-controlled, Double-blind, Parallel-group Study.	J Rheumatol		in press	

Yamazaki H, Nanki T, Miyasaka N, <u>Harigai M</u>	Methotrexate and trimethoprim-sulfamethoxazole use for PCP prophylaxis.	J Rheumatol	38(4)	777	2011
Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nakajima A, Atsumi T, Yasuda S, Tanaka Y, Saito K, Tohma S, Fujii T, Ihata A, Tamura N, Kawakami A, Sugihara T, Ito S, Miyasaka N, <u>Harigai M</u> , for the REAL Study Group	The REAL database reveals no significant risk for serious infection during treatment with methotrexate over 8 mg/week in patients with rheumatoid arthritis.	Mod Rheumatol	21(4)	444-8	2011
Koike R, Tanaka M, Komano Y, Sakai F, Sugiyama H, Nanki T, Ide H, Jodo S, Katayama K, Matsushima H, Miwa Y, Morita K, Nakashima H, Nakamura H, Natsumeda M, Sato Y, Semba S, Tateishi M, Miyasaka N, <u>Harigai M</u>	Tacrolimus-induced Pulmonary Injury in Rheumatoid Arthritis Patients.	Pulmonary Pharmacology and Therapeutics	24(4)	401-6	2011
Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Toma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, <u>Harigai M</u> , for the REAL Study Group	Incidence and risk factors for serious infection in rheumatoid arthritis patients treated with tumor necrosis factor (TNF) inhibitors; a report from the Registry of Japanese Rheumatoid Arthritis Patients for Long-Term Safety (REAL).	J Rheumatol	38(7)	1258-64	2011
Koike T, <u>Harigai M</u> , Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M	Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study.	Rheumatol Int		in press	

Koike T, <u>Harigai M</u> , Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M	Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis.	Rheumatol Int	in press		
Koike T, <u>Harigai M</u> , Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis.	Mod Rheumatol	21(4)	343-51	2011
Tanaka Y, <u>Harigai M</u> , Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Oba T, Yoshinari T, Baker D, and the GO-FORTH Study Group	Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study.	Ann Rheum Dis	in press		
Koike T, <u>Harigai M</u> , Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M	Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis.	Rheumatol Int	in press		
Koike T, <u>Harigai M</u> , Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Tanaka Y	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.	Mod Rheumatol	in press		
Koike T, <u>Harigai M</u> , Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Ito K, Yamanaka H	Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.	Ann Rheum Dis	70(12)	2148-51	2011
<u>Harigai M</u> , Takeuchi T, Tanaka Y, Matsubara T, Yamanaka H, Miyasaka N, for the BRIGHT study investigators group	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity.	Mod Rheumatol	in press		

(津谷 喜一郎)

[書 籍]

発表者氏名	論文タイトル名	書籍全体の編集者名	出版社名	出版年
		書籍名	出版地	ページ
寺岡章雄, 津谷喜一郎			日本評論社	2011
		日本で承認されていない薬を安全に 使うーコンパッショネート使用制度	東京	66-73
津谷喜一郎	CONSORT 声明	日本臨床薬理学会編	医学書院	2011
		臨床薬理学第3版	東京	72-74

[雑 誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Motoo Y, Seki T, <u>Tsutani K</u>	Traditional Japanese medicine, Kampo: Its history and current status.	Chinese Journal of Integrative Medicine	17(2)	85-7	2011
Kamioka H, <u>Tsutani K</u> , Mutoh Y, Okuizum H, Ohta M, et al	A systematic review of nonrandomized controlled trials on the curative effects of aquatic exercise.	International Journal of General Medicine	4	239-260	2011
Kitagawa M, <u>Tsutani K</u>	Duplicate publication cases in the field of Kampo (Japanese herbal medicine) in Japan.	Journal of Chinese Integrative Medicine	9(10)	1055-1060	2011
Sawata H, Tsutani K.	Funding and infrastructure among large-scale clinical trials examining cardiovascular diseases in Japan: evidence from a questionnaire survey.	BMC Med Res Methodol.	11	148	2011
五十嵐中, <u>津谷喜一郎</u>	薬剤経済学の基本的手法を学ぶ.	月刊薬事	53(2)	19-24	2011
赤沢 学, 草間真紀子, <u>津谷喜一郎</u>	フォーミュラリー作成と薬剤経済学.	月刊薬事	53(2)	31-37	2011
福澤 学, 井上雅夫, <u>津谷喜一郎</u>	日米における医薬品適応外使用とその 施策ー1990年代後半以降の歴史・現状・ 将来ー.	医薬品医療機器 レギュラトリー サイエンス	42(4)	346-356	2011
草間真紀子, 赤沢 学, <u>津谷喜一郎</u>	医療機関における採用医薬品集作成と 医薬品採否に関する実態調査.	臨床薬理	43(1)	43-49	2012

(井田 弘明)

[雑 誌]

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T, Mizushima T, Ichinose K, Nakamura H, Tsujino A, Kawakami A, Matsunaka M, Kasagi S, Kawano S, Kumagai S, Ohmura K, Mimori T, Hirano M, Ueno S, Tanaka K, Tanaka M, Toyoshima I, Sugino H, Yamakawa A, Tanaka K, Niikawa N, Furukawa F, Murata S, Eguchi K, Ida H, Yoshiura K	Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome.	Proc Natl Acad Sci USA	108	14914-14919	2011
Koga T, Okada A, Kawashiri S, Kita J, Suzuki T, Nakashima Y, Tamai M, Satoh K, Origuchi T, Iwamoto N, Yamasaki S, Nakamura H, Migita K, Ida H, Ueki Y, Eguchi K, Kawakami A	Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population.	Clin Exp Rheumatol	29	811-815	2011
Takei S, Hoshino T, Matsunaga K, Sakazaki Y, Sawada M, Oda H, Takenaka SI, Imaoka H, Kinoshita T, Honda S, Ida H, Fukuda TA, Aizawa H	Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis.	Arthritis Res Ther	13	R52	2011
To H, Yoshimatsu H, Tomonari M, Ida H, Tsurumoto T, Tsuji Y, Sonemoto E, Shimasaki N, Koyanagi S, Sasaki H, Ieiri I, Higuchi S, Kawakami A, Ueki Y, Eguchi K	Methotrexate chronotherapy is effective against rheumatoid arthritis.	Chronobiol Int	28	267-274	2011